Your browser doesn't support javascript.
loading
Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.
Bunse, Lukas; Sommerer, Claudia; Tan, Chin Leng; Korell, Felix; Schmitt, Anita; Hückelhoven-Krauss, Angela; Neuber, Brigitte; Mertens, Thomas; Platten, Michael; Green, Edward W; Zeier, Martin; Schmitt, Michael.
Afiliación
  • Bunse L; DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Sommerer C; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, 69117 Heidelberg, Germany.
  • Tan CL; Division of Nephrology, University Hospital Heidelberg, Renal Clinic Heidelberg, 69120 Heidelberg, Germany.
  • Korell F; DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Schmitt A; Faculty of Biosciences, Heidelberg University, 69117 Heidelberg, Germany.
  • Hückelhoven-Krauss A; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Neuber B; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Mertens T; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Platten M; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Green EW; Institute of Virology, University of Ulm, 89081 Ulm, Germany.
  • Zeier M; DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Schmitt M; Department of Neurology, MCTN, Medical Faculty Mannheim, Heidelberg University, 69117 Heidelberg, Germany.
Int J Mol Sci ; 23(3)2022 Jan 18.
Article en En | MEDLINE | ID: mdl-35162953
ABSTRACT
After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8+ T cells were characterized by bulk T-cell-receptor (TCR) repertoire sequencing and combined single-cell RNA and TCR sequencing. In patients mounting an immune response to the vaccine, a common SYE(N)E TCR motif known to bind CMVpp65 was detected. CMV-peptide-vaccination-responder patients had TCR features distinct from those of non-responders. In a non-responder patient, a monoclonal inflammatory T-cell response was detected upon CMV reactivation. The identification of vaccine-induced CMV-reactive TCRs motifs might facilitate the development of cellular therapies for patients wait-listed for kidney transplantation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Proteínas de la Matriz Viral / Infecciones por Citomegalovirus / Fallo Renal Crónico Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Proteínas de la Matriz Viral / Infecciones por Citomegalovirus / Fallo Renal Crónico Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Alemania